Psoriatic arthritis: Recent progress in pathophysiology and drug development

Arthritis Research and Therapy

Volumn 15, Issue 6, 2013, Pages

  Veale, Douglas J ^a,b  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; APREMILAST; BRODALIMUMAB; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLIMUMAB; IXEKIZUMAB; LEFLUNOMIDE; METHOTREXATE; PLACEBO; SALAZOSULFAPYRIDINE; SECUKINUMAB; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; USTEKINUMAB; ANTIRHEUMATIC AGENT;

ADAPTIVE IMMUNITY; BIOLOGICAL THERAPY; BONE EROSION; DISEASE DURATION; DRUG APPROVAL; DRUG BINDING; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; GENETICS; HUMAN; INNATE IMMUNITY; MOLECULAR BIOLOGY; MOLECULARLY TARGETED THERAPY; PATHOGENESIS; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PSORIATIC ARTHRITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; DRUG DEVELOPMENT;

ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; DRUG DISCOVERY; HUMANS; MOLECULAR TARGETED THERAPY;

EID: 84890756621     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4414     Document Type: Review

References (51)

1. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009, 361:496-509. 10.1056/NEJMra0804595, 19641206.
2. Veale D, Rogers S, Fitzgerald O. Classification of clinical subsets in psoriatic arthritis. Br J Rheumatol 1994, 33:133-138. 10.1093/rheumatology/33.2.133, 8162477.
3. Klaassen KM, van de Kerkhof PC, Pasch MC. Nail psoriasis: a questionnaire-based survey. Br J Dermatol 2013, 169:314-319. 10.1111/bjd.12354, 23550612.
4. McGonagle DG, Helliwell P, Veale D. Enthesitis in psoriatic disease. Dermatology 2012, 225:100-109. 10.1159/000341536, 23108016.
5. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, CASPAR Study Group Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006, 54:2665-2673. 10.1002/art.21972, 16871531, CASPAR Study Group.
6. Shbeeb M, Uramoto KM, Gibson LE, O'Fallon WM, Gabriel SE. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol 2000, 27:1247-1250.
7. Kane D, Pathare S. Early psoriatic arthritis. Rheum Dis Clin North Am 2005, 31:641-657. 10.1016/j.rdc.2005.07.009, 16287589.
8. Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D, FitzGerald O, Aletaha D, Balint P, Boumpas D, Braun J, Breedveld FC, Burmester G, Canete JD, de Wit M, Dagfinrud H, de Vlam K, Dougados M, Helliwell P, Kavanaugh A, Kvien TK, Landewe R, Luger T, Maccarone M, McGonagle D, McHugh N, McInnes IB, Ritchlin C, Sieper J, Tak PP, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012, 71:4-12. 10.1136/annrheumdis-2011-200350, 21953336.
9. Mease P, Genovese MC, Gladstein G, Kivitz AJ, Ritchlin C, Tak PP, Wollenhaupt J, Bahary O, Becker JC, Kelly S, Sigal L, Teng J, Gladman D. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum 2011, 63:939-948. 10.1002/art.30176, 21128258.
10. Ciocon DH, Kimball AB. PsO and psoriatic arthritis: separate or one and the same?. Br J Dermatol 2007, 157:850-860. 10.1111/j.1365-2133.2007.08148.x, 17725671.
11. Lambert JR, Wright V, Rajah SM, Moll JM. Histocompatibility antigens in psoriatic arthritis. Ann Rheum Dis 1976, 35:526-530. 10.1136/ard.35.6.526, 1006597, 1087552.
12. Gladman DD, Anhorn KA, Schachter RK, Mervart H. HLA antigens in psoriatic arthritis. J Rheumatol 1986, 13:586-592.
13. Apel M, Uebe S, Bowes J, Giardina E, Korendowych E, Juneblad K, Pasutto F, Ekici AB, McManus R, Ho P, Bruce IN, Ryan AW, Behrens F, Böhm B, Traupe H, Lohmann J, Gieger C, Wichmann HE, Padyukov L, Fitzgerald O, Alenius GM, McHugh NJ, Novelli G, Burkhardt H, Barton A, Reis A, Hüffmeier U. Variants in RUNX3 contribute to susceptibility to psoriatic arthritis, exhibiting further common ground with ankylosing spondylitis. Arthritis Rheum 2013, 65:1224-1231. 10.1002/art.37885, 23401011.
14. Hüffmeier U, Uebe S, Ekici AB, Bowes J, Giardina E, Korendowych E, Juneblad K, Apel M, McManus R, Ho P, Bruce IN, Ryan AW, Behrens F, Lascorz J, Böhm B, Traupe H, Lohmann J, Gieger C, Wichmann HE, Herold C, Steffens M, Klareskog L, Wienker TF, Fitzgerald O, Alenius GM, McHugh NJ, Novelli G, Burkhardt H, Barton A, Reis A. Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and PsO. Nat Genet 2010, 42:996-999. 10.1038/ng.688, 2981079, 20953186.
15. Ellinghaus E, Stuart PE, Ellinghaus D, Nair RP, Debrus S, Raelson JV, Belouchi M, Tejasvi T, Li Y, Tsoi LC, Onken AT, Esko T, Metspalu A, Rahman P, Gladman DD, Bowcock AM, Helms C, Krueger GG, Koks S, Kingo K, Gieger C, Wichmann HE, Mrowietz U, Weidinger S, Schreiber S, Abecasis GR, Elder JT, Weichenthal M, Franke A. Genome-wide meta-analysis of psoriatic arthritis identifies susceptibility locus at REL. J Invest Dermatol 2012, 132:1133-1140. 10.1038/jid.2011.415, 3305829, 22170493.
16. Nair RP, Duffin KC, Helms C, Ding J, Stuart PE, Goldgar D, Gudjonsson JE, Li Y, Tejasvi T, Feng BJ, Ruether A, Schreiber S, Weichenthal M, Gladman D, Rahman P, Schrodi SJ, Prahalad S, Guthery SL, Fischer J, Liao W, Kwok PY, Menter A, Lathrop GM, Wise CA, Begovich AB, Voorhees JJ, Elder JT, Krueger GG, Bowcock AM, Abecasis GR. Collaborative Association Study of PsO. Genome-wide scan reveals association of PsO with IL-23 and NF-κB pathways. Nat Genet 2009, 41:199-204. 10.1038/ng.311, 2745122, 19169254.
17. Bluett J, Barton A. What have genome-wide studies told us about psoriatic arthritis?. Curr Rheumatol Rep 2012, 14:364-368. 10.1007/s11926-012-0255-5, 22532288.
18. Jadon D, Tillett W, Wallis D, Cavill C, Bowes J, Waldron N, Dixon A, Sengupta R, Barton A, Korendowych E, McHugh NJ. Exploring ankylosing spondylitis-associated ERAP1, IL23R and IL12B gene polymorphisms in subphenotypes of psoriatic arthritis. Rheumatology (Oxford) 2013, 52:261-266.
19. Sherlock JP, Joyce-Shaikh B, Turner SP, Chao CC, Sathe M, Grein J, Gorman DM, Bowman EP, McClanahan TK, Yearley JH, Eberl G, Buckley CD, Kastelein RA, Pierce RH, Laface DM, Cua DJ. IL-23 induces spondyloarthropathy by acting on ROR-γt+CD3+CD4-CD8- entheseal resident T cells. Nat Med 2012, 18:1069-1076. 10.1038/nm.2817, 22772566.
20. Fearon U, Veale DJ. Pathogenesis of psoriatic arthritis. Clin Exp Dermatol 2001, 26:333-337. 10.1046/j.1365-2230.2001.00792.x, 11422185.
21. Eedy DJ, Johnston CF, Shaw C, Buchanan KD. Neuropeptides in PsO: an immunohistochemical and radioimmunoassay study. J Invest Dermatol 1991, 96:434-438. 10.1111/1523-1747.ep12469898, 2007781.
22. Veale D, Farrell M, FitzGerald O. Mechanisms of joint sparing in a patient with unilateral psoriatic arthritis and a long-standing hemiplegia. Br J Rheumatol 1993, 32:413-416. 10.1093/rheumatology/32.5.413, 7684307.
23. Punzi L, Pianon M, Bertazzolo N, Fagiolo U, Rizzi E, Rossini P, Todesco S. Clinical, laboratory and immunogenetic aspects of post-traumatic psoriatic arthritis: a study of 25 patients. Clin Exp Rheumatol 1998, 16:277-281.
24. Langevitz P, Baskila D, Gladman DD. Arthritis precipitated by physical trauma. J Rheumatol 1990, 17:695-697.
25. Mallbris L, Wolk K, Sánchez F, Ståhle M. HLA-Cw*06 associates with a twofold higher prevalence of positive streptococcal throat swab at the onset of PsO: a case control study. BMC Dermatol 2009, 9:5. 10.1186/1471-5945-9-5, 2696405, 19480679.
26. Espinoza LR, Berman A, Vasey FB, Cahalin C, Nelson R, Germain EF. Psoriatic arthritis and acquired immuno-deficiency syndrome. Arthritis Rheum 1988, 31:1034-1040. 10.1002/art.1780310815, 3408507.
27. Reinholz M, Ruzicka T, Schauber J. Cathelicidin LL-37: an antimicrobial peptide with a role in inflammatory skin disease. Ann Dermatol 2012, 24:126-135. 10.5021/ad.2012.24.2.126, 3346901, 22577261.
28. Nakajima K, Kanda T, Takaishi M, Shiga T, Miyoshi K, Nakajima H, Kamijima R, Tarutani M, Benson JM, Elloso MM, Gutshall LL, Naso MF, Iwakura Y, DiGiovanni J, Sano S. Distinct roles of IL-23 and IL-17 in the development of PsO-like lesions in a mouse model. J Immunol 2011, 186:4481-4489. 10.4049/jimmunol.1000148, 21346238.
29. Moran EM, Heydrich R, Ng CT, Saber TP, McCormick J, Sieper J, Appel H, Fearon U, Veale DJ. IL-17A expression is localised to both mononuclear and polymorphonuclear synovial cell infiltrates. PLoS One 2011, 6:e24048. 10.1371/journal.pone.0024048, 3161104, 21887369.
30. Wei L, Laurence A, Elias KM, O'Shea JJ. IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner. J Biol Chem 2007, 282:34605-34610. 10.1074/jbc.M705100200, 2323680, 17884812.
31. Braverman IM, Yen A. Microcirculation in psoriatic skin. J Invest Dermatol 1974, 62:493-502. 10.1111/1523-1747.ep12681007, 4823589.
32. Gao W, Sweeney C, Walsh C, Rooney P, McCormick J, Veale DJ, Fearon U. Notch signalling pathways mediate synovial angiogenesis in response to vascular endothelial growth factor and angiopoietin 2. Ann Rheum Dis 2013, 72:1080-1088. 10.1136/annrheumdis-2012-201978, 3664379, 23161900.
33. Ng CT, Biniecka M, Kennedy A, McCormick J, Fitzgerald O, Bresnihan B, Buggy D, Taylor CT, O'Sullivan J, Fearon U, Veale DJ. Synovial tissue hypoxia and inflammation in vivo. Ann Rheum Dis 2010, 69:1389-1395. 10.1136/ard.2009.119776, 2946116, 20439288.
34. Marzaioli V, McMorrow JP, Angerer H, Gilmore A, Crean D, Zocco D, Rooney P, Veale D, Fearon U, Gogarty M, McEvoy AN, Stradner MH, Murphy EP. Histamine contributes to increased RANKL to osteoprotegerin ratio through altered nuclear receptor 4A activity in human chondrocytes. Arthritis Rheum 2012, 64:3290-3301. 10.1002/art.34554, 22674155.
35. Anandarajah AP, Schwarz EM, Totterman S, Monu J, Feng CY, Shao T, Haas-Smith SA, Ritchlin CT. The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oedema in patients with psoriatic arthritis. Ann Rheum Dis 2008, 67:296-301.
36. Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH, de Vlam K, Fiorentino D, Fitzgerald O, Gottlieb AB, McHugh NJ, Nash P, Qureshi AA, Soriano ER, Taylor WJ, Group for Research and Assessment of PsO and Psoriatic Arthritis (GRAPPA) Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009, 68:1387-1394. 10.1136/ard.2008.094946, 2719080, 18952643, Group for Research and Assessment of PsO and Psoriatic Arthritis (GRAPPA).
37. Mease P. Update on treatment of psoriatic arthritis. Bull NYU Hosp Jt Dis 2012, 70:167-171.
38. Rodgers M, Epstein D, Bojke L, Yang H, Craig D, Fonseca T, Myers L, Bruce I, Chalmers R, Bujkiewicz S, Lai M, Cooper N, Abrams K, Spiegelhalter D, Sutton A, Sculpher M, Woolacott N. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess 2011, 15:i-xxi:1-329.
39. Saad AA, Ashcroft DM, Watson KD, Symmons DP, Noyce PR, Hyrich KL, BSRBR Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2010, 49:697-705. BSRBR.
40. Kavanaugh A, van der Heijde D, McInnes IB, Mease P, Krueger GG, Gladman DD, Gomez-Reino J, Papp K, Baratelle A, Xu W, Mudivarthy S, Mack M, Rahman MU, Xu Z, Zrubek J, Beutler A. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum 2012, 64:2504-2517. 10.1002/art.34436, 22378566.
41. Gladman D, Fleischmann R, Coteur G, Woltering F, Mease PJ. Effect of certolizumab pegol on the multiple facets of psoriatic arthritis as reported by patients with and without prior anti-TNF exposure: 24-week patient-reported outcome results of Rapid-PSA study. Ann Rheum Dis 2013, 72(Suppl):s260.
42. Chimenti MS, Saraceno R, Chiricozzi A, Giunta A, Chimenti S, Perricone R. Profile of certolizumab and its potential in the treatment of psoriatic arthritis. Drug Des Devel Ther 2013, 7:339-348. 3633576, 23620660.
43. Veale DJ. New therapies and new goals for psoriatic arthritis. Arthritis Rheum 2011, 63:874-876. 10.1002/art.30173, 21128255.
44. McInnes IB, Sieper J, Braun J, Emery P, van der Heijde D, Isaacs JD, Dahmen G, Wollenhaupt J, Schulze-Koops H, Kogan J, Ma S, Schumacher MM, Bertolino AP, Hueber W, Tak PP. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis 2013, : [Epub ahead of print].
45. McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, Brodmerkel C, Li S, Wang Y, Mendelsohn AM, Doyle MK, PSUMMIT 1 Study Group Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013, 382:780-789. 10.1016/S0140-6736(13)60594-2, 23769296, PSUMMIT 1 Study Group.
46. Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, Aras G, Li J, Russell CB, Thompson EH, Baumgartner S. Brodalumab, an anti-interleukin-17-receptor antibody for PsO. N Engl J Med 2012, 366:1181-1189. 10.1056/NEJMoa1109017, 22455412.
47. Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, Braun D, Banerjee S. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque PsO. N Engl J Med 2012, 366:1190-1199. 10.1056/NEJMoa1109997, 22455413.
48. Saber TP, Ng CT, Renard G, Lynch BM, Pontifex E, Walsh CA, Grier A, Molloy M, Bresnihan B, Fitzgerald O, Fearon U, Veale DJ. Remission in psoriatic arthritis: is it possible and how can it be predicted?. Arthritis Res Ther 2010, 12:R94. 10.1186/ar3021, 2911878, 20482783.
49. Kavanaugh A, Mease PJ, Adebajo AO, Wollenhaupt J, Hu C, Shah K, Stevens RM, Gomez-Reino JJ. Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis. Ann Rheum Dis 2013, 72(Suppl):s0001.
50. van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, Cardiel MH, Cohen S, Nash P, Song YW, Tegzova D, Wyman BT, Gruben D, Benda B, Wallenstein G, Krishnaswami S, Zwillich SH, Bradley JD, Connell CA, ORAL Scan Investigators Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 2013, 65:559-570. 10.1002/art.37816, 23348607, ORAL Scan Investigators.
51. Mamolo C, Harness J, Tan H, Menter A. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe PsO. J Eur Acad Dermatol Venereol 2013, : [Epub ahead of print].